Catalent Pharma Solutions has appointed Alessandro Maselli as the new senior vice president (SVP) of global operations, while Christine Dolan will assume the role of SVP of global product development. Mr. Maselli previously acted as vice president of operations for Catalent’s drug delivery solutions business in Europe. Prior to this, he was general manager of Catalent’s Zydis orally disintegrating tablet facility in Swindon, UK, and held a number of other senior management and operational roles, having joined the organization from Alstom in 2010. Before joining Alstom, Mr. Maselli had worked in business management and operations positions for SGS and ABB respectively.
Steve Leonard, who previously held the position of SVP of global operations, has decided to leave the company in early 2017, but will continue in an advisory position until that time, in order to assist with the transition.
Ms. Dolan was appointed vice president, global softgel operations in November 2013, with responsibility for Catalent’s 11 Softgel manufacturing and development sites. In this role, she had operational responsibility for more than 3,500 employees. She began her career with Catalent in 2009 in global quality, and in 2010 was named general manager for Catalent’s Woodstock, Illinois, sterile technologies facility. She had previously acted as vice president of operations for the development and clinical services business unit, with operational responsibilities for five of Catalent’s facilities providing clinical manufacturing, packaging, and analytical development of both large and small molecules.
Following Catalent’s acquisition of Aptuit’s clinical trials business in 2011, Ms. Dolan was named vice president and general manager of development and analytical solutions. Prior to Catalent, she worked as a microbiologist for Smith & Nephew Solopak, and also Amersham Health and GE Healthcare, where she served in various leadership roles.
Source: Catalent Pharma Solutions